Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.39 |
| ▸ | PIM1 | P11309 | 8/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5326287 | 0.99 | EPHX2 (0.38) | EPHX2DYRK1APIM1TYRO3LDHA | |
| SCHEMBL8221773 | 0.89 | PIM1 (0.35) | DYRK1APIM1TYRO3KCNH2 | |
| Hydrochloric Acid SCHEMBL5331829 | 0.86 | ALDH1A1 (0.43) | EPHX2 | |
| SCHEMBL5330081 | 0.85 | KDM1A (0.38) | EPHX2DYRK1A | |
| Hydrochloric Acid SCHEMBL5329078 | 0.84 | KDM1A (0.37) | EPHX2DYRK1A | |
| SCHEMBL5330105 | 0.83 | EPHX2 (0.41) | EPHX2 | |
| Hydrochloric Acid SCHEMBL5331732 | 0.83 | EPHX2 (0.40) | EPHX2 | |
| SCHEMBL14340786 | 0.82 | ALDH1A1 (0.46) | — | |
| SCHEMBL5330842 | 0.81 | ALDH1A1 (0.38) | DYRK1A | |
| SCHEMBL5323440 | 0.81 | CA12 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | US | claimed |
| WO-2007148113-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | WO | claimed |
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299113-A1 | Metabotropic glutamate receptor modulators | GRM1, GRM2, GRM3 | EPHX2 3181/4885DYRK1A 2287/4885PIM1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.